End Markets
FlyPharma targets animal nutrition markets where biologics are already economically justified, operationally necessary, and increasingly unavoidable.
FlyPharma targets high-volume protein production systems where biologics remain under-penetrated due to cost and production constraints.
The platform enables feed-grade economics across poultry, swine, and aquaculture — markets operating at global industrial scale.
Poultry
Approximately 70 billion broiler chickens are produced annually — over 99% in intensive systems where small efficiency gains have material economic impact.
Biologics remain under-penetrated at feed scale due to production cost constraints. FlyPharma’s platform enables cost structures aligned with industrial poultry economics.
Biologics remain under-penetrated at feed scale due to production cost constraints. FlyPharma’s platform enables cost structures aligned with industrial poultry economics.
The reality
Gut health challenges such as necrotic enteritis remain structurally embedded in poultry production. At the same time, preventative antibiotic use is being phased down across most major producing regions. This has created a persistent gap between disease pressure and available tools.
Why FlyPharma enters here
FlyPharma produces immune-active feed ingredients designed for continuous, preventative use at commercial scale. By delivering biologics at feed-grade economics, FlyPharma enables approaches that were previously impractical outside pharmaceuticals.
Why it matters
- Poultry production already spends heavily on managing gut health
- Solutions must work across billions of birds, not in controlled trials
- Reduces reliance on antibiotics in high-density production systems.
- Cost, consistency, and supply reliability are decisive
Swine
Global swine production exceeds 1 billion animals annually, operating within tightly managed, high-density systems where health stability directly impacts feed efficiency and margin.
The reality
Post-weaning stress and gut disease remain persistent performance constraints. While antibiotics have historically mitigated these risks, regulatory and market pressures are steadily reducing their role in commercial systems.
Why FlyPharma enters here
Biologic interventions have struggled to scale due to cost and delivery complexity. FlyPharma’s platform enables feed-grade biologic ingredients aligned with modern swine production — designed for consistency, simplicity, and integration into existing feed workflows.
Why it matters
- Swine systems require consistency across scale
- Interventions that add complexity do not survive long-term
- Feed-based solutions remain the most scalable delivery vector
Aquaculture
In salmon and prawn production, pigmentation is mandatory and directly linked to pricing and consumer acceptance.
The reality
- ~5.6M tonnes global farmed shrimp (2023).
- Pigmentation is dosed in feed: ~50–70 mg/kg astaxanthin in salmonids.
- Most supply is synthetic because it scales on petrochemical economics.
Natural alternatives have struggled to compete due to cost and production constraints.
Why FlyPharma enters here
FlyPharma produces natural astaxanthin with equivalent functional properties to synthetic alternatives, alongside antioxidant benefits. Crucially, it does so using a platform designed for industrial scale, not niche production.
Why it matters
- Colour drives pricing and consumer acceptance
- Producers already pay for pigmentation
- A scalable natural alternative changes the equation
Eggs
Global egg production exceeds 95 million tonnes annually. More than 60% is produced in industrial systems, where yolk colour is typically tuned through feed carotenoids.
The reality
Yolk colour is a direct retail and consumer signal. Carotenoid pigments are routinely included in feed at ppm levels to achieve target colour scores. Synthetic sources remain common due to cost and consistency.
Why FlyPharma enters here
FlyPharma’s platform enables natural pigmentation delivered through standard feed inclusion, aligning with existing formulation practices and production workflows.
Why it matters
- Egg markets reward visual consistency
- Pigmentation is already embedded in feed budgets
- Inputs must be scalable, reliable, and operationally invisible
Partner With FlyPharma
FlyPharma engages selectively.
If you are an integrated producer, feed manufacturer, strategic partner, or investor interested in deploying the next generation of biologics production at scale, we welcome the conversation.